CUE

$31.08+$0.66 (+2.17%)prev close

Compare

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Market cap

$127.8M

4M shares

52-week range

$4.97 – $45.50

64% from low

Sector

PHARMACEUTICAL PREPARATIONS

Exchange

NASDAQ

Change$-273.72

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$13M	+96.9%	$-6.64	$-6.64–$-6.64	—	1
2027	$1M	-92.2%	$-9.45	$-9.45–$-9.45	—	1
2028	$1M	+0.0%	$-15.30	$-15.30–$-15.30	—	1
2029	$1M	+0.0%	$-15.60	$-15.60–$-15.60	—	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 7 of the last 8 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-05-14	$-3.30	$-1.08	+67.3%
2026-03-16	$-2.70	$0.30	+111.1%
2025-11-12	$-0.10	$-0.07	+30.0%
2025-08-12	$-0.13	$-0.09	+30.8%
2025-05-12	$-0.14	$-0.17	-21.4%
2025-03-31	$-0.16	$-0.13	+18.8%
2024-11-14	$-0.20	$-0.17	+15.0%
2024-08-19	$-0.29

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
CUECue Biopharma, Inc.	$31.08	+2.17%	$82M	—
BRNSBarinthus Biotherapeutics plc	$0.60	+2.99%	$25M	—
COEPCoeptis Therapeutics Holdings, Inc.	$10.99	-8.57%	$39M	—
EQEquillium, Inc.	$2.01	-7.80%	$127M	—
IOBTIO Biotech, Inc.	$0.01	-27.59%

Cue Biopharma, Inc.

Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.

www.cuebiopharma.com

Employees: 29
IPO / List date: Jan 2, 2018
HQ: BOSTON, MA

Held by traders on TradeandTell

No one on the platform currently holds CUE.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in CUE as of their last filing.

Insider activity (SEC Form 4)

Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.

Insider activity (SEC Form 4)

Stock splits

Execution date	Ratio
2026-04-24	1-for-30reverse

Recent trades on TradeandTell

No one on the platform has traded CUE yet.

$CUE chatter on StockTwits

Jonny Doom And Gloom@Doom_Gloom_AR3d
On this 10th day of August 2026 I purchased some $CUE about 5% of port. Good luck, ige differentiation is needed. Scientifically has a chance there are no guarantees in this business.
View on StockTwits ↗
Hov@OnlyFibsBullish3d
Cue Biopharma, Inc. $CUE (8h) Bullish Flow: Retail paper is getting shaken out while heavy-pocketed buyers scoop every dip along the lower trendline. Big bids are stacking up at the floor, laying the foundation for a massive secondary expansion wave. 🐂 💧 Bull Key Level: $25.97 (Bull confirmation to smash local channel resistance and trigger a high-velocity squeeze) 🐂 🔥 Bear Key Level: $22.50 (Key structural floor and critical multi-week demand zone to defend) 🐻 ⚠️ Targets: $35.00 / $45.52 💰 🍺 Why: The 8-hour chart is coiling like a springboard right on top of a massive volume shelf. Holding $22.50 keeps this ascending wedge primed for a violent rip through $35.00 straight up to $45.52. #cue | #cuebiopharma | #healthcare | #stocktrading | #hovdid
View on StockTwits ↗